Cot/tpl2-MKK1/2-Erk1/2 controls mTORC1-mediated mRNA translation in Toll-like receptor-activated macrophages

Molecular Biology of the Cell

Volumn 23, Issue 15, 2012, Pages 2982-2992

  López Pelaéz, Marta ^a   Fumagalli, Stefano ^b   Sanz, Carlos ^a   Herrero, Clara ^a   Guerra, Susana ^c   Fernandez, Margarita ^a   Alemany, Susana ^a  

^a CSIC   (Spain)

^b INSERM   (France)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN S6; TPL2 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROTEIN; UNCLASSIFIED DRUG; ZYMOSAN;

ANIMAL CELL; ARTICLE; DISSOCIATION; GENE EXPRESSION; GENE INACTIVATION; GENE SILENCING; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA TRANSLATION; TOLL LIKE RECEPTOR ACTIVATED MACROPHAGE;

ANIMALS; HUMANS; INFLAMMATION; LIM DOMAIN PROTEINS; LIPOPOLYSACCHARIDES; MACROPHAGES; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864767892     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E12-02-0135     Document Type: Article

References (67)

1. Akira S, Takeda K (2004). Toll-like receptor signalling. Nat Rev Immunol 4, 499-511.
2. Anderson P (2008). Post-transcriptional control of cytokine production. Nat Immunol 9, 353-359.
3. Anderson P (2010). Post-transcriptional regulons coordinate the initiation and resolution of inflammation. Nat Rev Immunol 10, 24-35.
4. Anjum R, Blenis J (2008). The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 9, 747-758.
5. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P (2007). The selectivity of protein kinase inhibitors: a further update. Biochem J 408, 297-315.
6. Ballester A, Velasco A, Tobena R, Alemany S (1998). Cot kinase activates tumor necrosis factor-alpha gene expression in a cyclosporin A-resistant manner. J Biol Chem 273, 14099-14106.
7. Banerjee A, Gugasyan R, McMahon M, Gerondakis S (2006). Diverse Toll-like receptors utilize Tpl2 to activate extracellular signal-regulated kinase (ERK) in hemopoietic cells. Proc Natl Acad Sci USA 103, 3274-3279.
8. Buxade M, Parra JL, Rousseau S, Shpiro N, Marquez R, Morrice N, Bain J, Espel E, Proud CG (2005). The Mnks are novel components in the control of TNF alpha biosynthesis and phosphorylate and regulate hnRNP A1. Immunity 23, 177-189.
9. Caivano M, Rodriguez C, Cohen P, Alemany S (2003). 15-Deoxy-delta12,14- prostaglandin J2 regulates endogenous Cot MAPK kinase kinase 1 activity induced by lipopolysaccharide. J Biol Chem 278, 52124-52130.
10. Carriere A, Cargnello M, Julien LA, Gao H, Bonneil E, Thibault P, Roux PP (2008). Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol 18, 1269-1277.
11. Cohen P (2009). Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol 21, 317-324.
12. Colina R et al. (2008). Translational control of the innate immune response through IRF-7. Nature 452, 323-328.
13. Chaurasia B, Mauer J, Koch L, Goldau J, Kock AS, Bruning JC (2010). Phosphoinositide-dependent kinase 1 provides negative feedback inhibition to Toll-like receptor-mediated NF-kappaB activation in macrophages. Mol Cell Biol 30, 4354-4366.
14. Chen CY, Shyu AB (1995). AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 20, 465-470.
15. Cho J, Tsichlis PN (2005). Phosphorylation at Thr-290 regulates Tpl2 binding to NF-kappaB1/p105 and Tpl2 activation and degradation by lipopolysaccharide. Proc Natl Acad Sci USA 102, 2350-2355.
16. Das S, Cho J, Lambertz I, Kelliher MA, Eliopoulos AG, Du K, Tsichlis PN (2005). Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner. J Biol Chem 280, 23748-23757.
17. del Prete MJ, Vernal R, Dolznig H, Mullner EW, Garcia-Sanz JA (2007). Isolation of polysome-bound mRNA from solid tissues amenable for RT-PCR and profiling experiments. RNA 13, 414-421.
18. Dumitru CD et al. (2000). TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103, 1071-1083.
19. Fukao T, Koyasu S (2003). PI3K and negative regulation of TLR signaling. Trends Immunol 24, 358-363.
20. Gaestel M, Kotlyarov A, Kracht M (2009). Targeting innate immunity protein kinase signalling in inflammation. Nat Rev Drug Discov 8, 480-499.
21. Gandara ML, Lopez P, Hernando R, Castano JG, Alemany S (2003). The COOH-terminal domain of wild-type Cot regulates its stability and kinase specific activity. Mol Cell Biol 23, 7377-7390.
22. Gantke T, Sriskantharajah S, Ley SC (2011). Regulation and function of TPL-2, an IkappaB kinase-regulated MAP kinase kinase kinase. Cell Res 21, 131-145.
23. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM (2003). Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 197, 1107-1117.
24. Garcia-Martinez JM, Alessi DR (2008). mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416, 375-385.
25. Gingras AC, Raught B, Sonenberg N (1999). eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68, 913-963.
26. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM (2006). Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11, 859-871.
27. Guo H, Ingolia NT, Weissman JS, Bartel DP (2010). Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835-840.
28. Hao S, Baltimore D (2009). The stability of mRNA influences the temporal order of the induction of genes encoding inflammatory molecules. Nat Immunol 10, 281-288.
29. Hatziapostolou M, Koukos G, Polytarchou C, Kottakis F, Serebrennikova O, Kuliopulos A, Tsichlis PN (2011). Tumor progression locus 2 mediates signal-induced increases in cytoplasmic calcium and cell migration. Sci Signal 4, ra55.
30. Hellen CU, Sarnow P (2001). Internal ribosome entry sites in eukaryotic mRNA molecules. Genes Dev 15, 1593-1612.
31. Huo Y, Iadevaia V, Yao Z, Kelly I, Cosulich S, Guichard S, Foster LJ, Proud CG (2012). Stable isotope-labelling analysis of the impact of inhibition of the mammalian target of rapamycin on protein synthesis. Biochem J 444, 141-151.
32. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G (1997). Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J 16, 3693-3704.
33. Kaiser F et al. (2009). TPL-2 negatively regulates interferon-beta production in macrophages and myeloid dendritic cells. J Exp Med 206, 1863-1871.
34. Kawai T, Akira S (2011). Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34, 637-650.
35. Kotenko SV, Krause CD, Izotova LS, Pollack BP, Wu W, Pestka S (1997). Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J 16, 5894-5903.
36. Laplante M, Sabatini DM (2009). mTOR signaling at a glance. J Cell Sci 122, 3589-3594.
37. Lopez-Pelaez M, Soria-Castro I, Bosca L, Fernandez M, Alemany S (2011). Cot/tpl2 activity is required for TLR-induced activation of the Akt p70 S6k pathway in macrophages: implications for NO synthase 2 expression. Eur J Immunol 41, 1733-1741.
38. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP (2005). Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179-193.
39. Marzec M, Liu X, Wysocka M, Rook AH, Odum N, Wasik MA (2011). Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells. PLoS One 6, e24849.
40. Mazumder B, Li X, Barik S (2010). Translation control: a multifaceted regulator of inflammatory response. J Immunol 184, 3311-3319.
41. Meyuhas O (2000). Synthesis of the translational apparatus is regulated at the translational level. Eur J Biochem 267, 6321-6330.
42. Mielke LA, Elkins KL, Wei L, Starr R, Tsichlis PN, O'Shea JJ, Watford WT (2009). Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1 beta production. J Immunol 183, 7984-7993.
43. O'Neill LA, Bowie AG (2007). The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7, 353-364.
44. Patursky-Polischuk I, Stolovich-Rain M, Hausner-Hanochi M, Kasir J, Cybulski N, Avruch J, Ruegg MA, Hall MN, Meyuhas O (2009). The TSC-mTOR pathway mediates translational activation of TOP mRNAs by insulin largely in a raptor- or rictor-independent manner. Mol Cell Biol 29, 640-649.
45. Pearce LR, Komander D, Alessi DR (2010). The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 11, 9-22.
46. Pestova TV, Kolupaeva VG, Lomakin IB, Pilipenko EV, Shatsky IN, Agol VI, Hellen CU (2001). Molecular mechanisms of translation initiation in eukaryotes. Proc Natl Acad Sci USA 98, 7029-7036.
47. Rodriguez C, Lopez P, Pozo M, Duce AM, Lopez-Pelaez M, Fernandez M, Alemany S (2008). COX2 expression and Erk1/Erk2 activity mediate Cot-induced cell migration. Cell Signal 20, 1625-1631.
48. Rodriguez C, Pozo M, Nieto E, Fernandez M, Alemany S (2006). TRAF6 and Src kinase activity regulates Cot activation by IL-1. Cell Signal 18, 1376-1385.
49. Rousseau S, Morrice N, Peggie M, Campbell DG, Gaestel M, Cohen P (2002). Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 and its interaction with cytokine mRNAs. EMBO J 21, 6505-6514.
50. Rousseau S, Papoutsopoulou M, Symons A, Cook D, Lucocq JM, Prescott AR, O'Garra A, Ley SC, Cohen P (2008). TPL2-mediated activation of ERK1 and ERK2 regulates the processing of pre-TNF alpha in LPS-stimulated macrophages. J Cell Sci 121, 149-154.
51. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J (2004). Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 101, 13489-13494.
52. Roux PP, Blenis J (2004). ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68, 320-344.
53. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J, Sonenberg N, Blenis J (2007). RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282, 14056-14064.
54. Sachs AB, Varani G (2000). Eukaryotic translation initiation: there are (at least) two sides to every story. Nat Struct Biol 7, 356-361.
55. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
56. Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozma SC (1998). Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J 17, 6649-6659.
57. Soria-Castro I, Krzyzanowska A, Pelaez ML, Regadera J, Ferrer G, Montoliu L, Rodriguez-Ramos R, Fernandez M, Alemany S (2010). Cot/tpl2 (MAP3K8) mediates myeloperoxidase activity and hypernociception following peripheral inflammation. J Biol Chem 285, 33805-33815.
58. Stafford MJ, Morrice NA, Peggie MW, Cohen P (2006). Interleukin-1 stimulated activation of the COT catalytic subunit through the phosphorylation of Thr290 and Ser62. FEBS Lett 580, 4010-4014.
59. Tamura T, Yanai H, Savitsky D, Taniguchi T (2008). The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 26, 535-584.
60. Tang H, Hornstein E, Stolovich M, Levy G, Livingstone M, Templeton D, Avruch J, Meyuhas O (2001). Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation. Mol Cell Biol 21, 8671-8683.
61. Thomson AW, Turnquist HR, Raimondi G (2009). Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9, 324-337.
62. Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM (2012). A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485, 109-113.
63. Topisirovic I, Svitkin YV, Sonenberg N, Shatkin AJ (2011). Cap and cap-binding proteins in the control of gene expression. Wiley Interdiscip Rev RNA 2, 277-298.
64. Vougioukalaki M, Kanellis DC, Gkouskou K, Eliopoulos AG (2011). Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett 304, 80-89.
65. Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG (2001). Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 20, 4370-4379.
66. Waterfield MR, Zhang M, Norman LP, Sun SC (2003). NF-kappaB1/p105 regulates lipopolysaccharide-stimulated MAP kinase signaling by governing the stability and function of the Tpl2 kinase. Mol Cell 11, 685-694.
67. Weichhart T, Saemann MD (2009). The multiple facets of mTOR in immunity. Trends Immunol 30, 218-226.